ACTION OF 2-ACETOXY-TRIFLUOROMETHYLBENZOIC ACID (TRIFLUSAL) ON PLATELET-FUNCTION AFTER REPEATED ORAL-ADMINISTRATION IN MAN - A PHARMACOLOGICAL CLINICAL-STUDY

The efficacy and safety of Triflusal capsules given to patients at thr ombogenetic risk because of platelet hyperaggretation were investigate d in a controlled study involving 15 patients (9 males and 6 females, mean age 65.7 years) who were given 300 mg/day of Triflusal during the first 5 days and 600 mg/day during the following 5 days. Subsequently , after 7 days of wash-out all these patients received placebo for 10 days, one capsule for the first 5 days and 2 capsules for the followin g 5 days. The platelet antiaggregant activity of the drug was evaluate d by means of Born's platelet activation test. Specific tests were als o made to assess the effect of this substance on platelet release and the coagulation system. The system was evaluated by measuring the most important clinical chemistry and clinical haematology indexes of haem atopoietic, hepatic, renal and metabolic functions. Arterial blood pre ssure and heart rate values were also recorded. All the 15 patients co mpleted the study. It was found that the Trifusal treatment led to a s ignificant mean reduction of the indexes chosen as markers of thrombop hilia or platelet hyperaggregation in vivo. It did not affect the norm al haemostatic-coagulation process and was well tolerated by the patie nts. The subsequent placebo treatment did not induce any platelet anti aggregant effects.